Brief: Crinetics Says TouCAHn Study Is Ongoing, With Topline Results From Complete Study Expected In H2 2024

Crinetics Pharmaceuticals

03/06/2024 18:10

June 3 (Reuters) - Crinetics Pharmaceuticals Inc
 CRNX.O :
    * CRINETICS ANNOUNCES POSITIVE INITIAL FINDINGS AT ENDO 2024
FOR
ATUMELNANT IN TWO ONGOING, OPEN-LABEL STUDIES FOR THE TREATMENT
OF CONGENITAL ADRENAL HYPERPLASIA (CAH) AND ACTH-DEPENDENT
CUSHING’S SYNDROME (ADCS)
    * CRINETICS PHARMACEUTICALS INC - TOUCAHN STUDY IS ONGOING,
WITH
TOPLINE RESULTS FROM COMPLETE STUDY EXPECTED IN SECOND HALF OF
2024

Source text for Eikon:  ID:nGNX6tMWtF 
Further company coverage:  CRNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))